Syschem (India) share price, P/E, ROE & financials

Syschem (India) (BSE: SYSCHEM) had a P/E of 28.7× on 6 Nov 2026, in line with the industry P/E of 28.7×, and the shares are 48% below their 52-week high. Its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 71% and 34% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹169 Cr, ranked 101st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 46% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹32.94
Day high: ₹33.78
Day low: ₹31.50
Prev. close: ₹32.26
Volume: 23K

Health check

2 good · 1 fair · 3 to check

ReturnsBehind
−45.9% over a year, better than 0 of 7 peers.
Price tagIn line
P/E 28.7 vs industry 28.7.
GrowthStrong
Sales +71.3%, profit +34.3% a year over 3 years.
ProfitabilityWeak
ROCE 11.5% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
Red flags2 to check
Return on equity is low at 6.5%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹169 Cr, #101 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹666 Cr · profit ₹8 Cr

Market cap: ₹169 Cr; Small cap
P/E: 28.7; Industry 28.7
Price to book: 1.20; Peers 4.99
Dividend yield: 0.00%
ROE: 6.5%; Peers 14.7%
ROCE: 11.5%; Peers 17.9%
Debt to equity: 0.01; Debt ₹0.87 Cr
EPS (TTM): ₹1.10
OPM (TTM): 3.3%; Net margin 1.1%
Sales growth: +9.4%; Latest quarter vs a year ago
Profit growth: +0.7%; Latest quarter vs a year ago
Price to sales: 0.25; EV/EBITDA 8.1

Strengths

Practically debt-free.

Risks to check

Return on equity is low at 6.5%.
48% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Syschem (India)

Syschem (India) Limited engages in the production and sale of active pharmaceuticals ingredients (API), intermediates, and bulk drugs in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, and cefadroxil. The company also engages in the distillation of specialist solvents, such as methonel, acetonitrile, ethyl acetate, and THF; and contract…

Headquarters: Chandigarh
Employees: 135
Sector: Healthcare
ISIN: INE121D01036
Website: syschem.in

Price range

52 weeks

₹28.81₹60.95

Today

₹31.50₹33.78

Avg volume (3M): 42.9K
1-year return: minus 45.9%
From 52-week high: minus 48.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
SYSCHEMSyschem (India)	31.61	minus 2.01%	169	28.7	1.20	11.5%	6.5%	3.3%	71.3%	34.3%	0.00%	minus 45.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
104	141	248	109	113
100	136	239	109	109
3.3	6	9.4	0.5	4.4
3.2%	4.2%	3.8%	0.5%	3.9%
0	0	0	0	0
0	0.2	2	0.5	0.7
0.8	0.8	1.7	1.6	1.6
0	–	–	–	–
2.5	5	5.6	−1.5	2.1
25.5%	16.0%	68.9%	−14.8%	10.3%
1.9	4.2	1.7	−1.7	1.9
0.34	0.74	0.31	-0.31	0.36

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +71.3%
Profit CAGR 3Y: +34.3%
EPS CAGR 3Y: +10.8%
ROE: 6.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
130	233	386	655
–	+79.1%	+65.5%	+69.6%
122	226	382	634
8.6	7	4	21.1
6.6%	3.0%	1.0%	3.2%
0.2	0.2	0	−2.2
0	0.3	0.1	0
2.7	2.8	2.9	4.1
–	−0	−0	–
6.2	4.1	1	14.8
26.6%	32.9%	54.5%	26.1%
4.5	2.8	0.5	10.9
–	minus 38.8%	minus 83.3%	+2275.4%
1.42	0.78	0.11	1.93

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
31.9	39.9	43.5	49
−9.6	17.1	47.8	73.4
1.6	0.5	–	0.4
68.8	107	126	169
92.7	164	217	292
30.8	34.7	53.4	67.6
0.1	4.1	0.3	–
0.7	0.1	2.1	9.4
61.1	125	161	215
92.7	164	217	292

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−8.5	−25.6	−10.1	7.6
−1.6	−6.5	−21.7	−19.6
10.7	31.6	33.8	17.9
0.5	−0.5	2	6
−2	−6.7	−21.7	−18.3
−10.5	−32.3	−31.8	−10.7

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you